DEF: Vaxart Seeks Reverse Stock Split to Regain Nasdaq Compliance

Vaxart, Inc. is seeking stockholder approval for a reverse stock split, ranging from 1-for-5 to 1-for-20, aimed at increasing its share price to meet Nasdaq's minimum bid requirement and avoid delisting.

Summary

• Vaxart, Inc. is holding a Special Meeting of Stockholders on September 5, 2025, to vote on a proposal to amend its Restated Certificate of Incorporation.
• The amendment would effect a reverse stock split of issued common shares by a ratio of not less than 1-for-5 and not more than 1-for-20, with the exact ratio to be determined by the board of directors.
• If the reverse stock split is effected, the number of authorized common shares will be proportionally decreased; for example, a 1-for-5 split would reduce authorized shares from 350,000,000 to 70,000,000.
• The primary purpose of the reverse stock split is to increase the per share price of the company's common stock to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
• Vaxart received a delisting notification from Nasdaq on July 1, 2025, due to non-compliance with the minimum bid price rule, leading to trading suspension on Nasdaq on July 8, 2025.
• The company's common stock began trading on the OTCQX under the symbol VXRT on July 8, 2025, with a closing price of $0.4180 per share as of July 23, 2025.
• The company is appealing Nasdaq's delisting decision, and its shares remain listed on Nasdaq while the appeal is pending.

Sentiment

Score: 3

Explanation: The necessity of a reverse stock split due to Nasdaq delisting is a significant negative indicator of the company's current market standing. While the proposed action is a necessary step to address a critical listing issue, it does not reflect positive operational or financial performance. The outcome of the split and its impact on investor confidence and Nasdaq compliance remain uncertain, as explicitly stated in the risks.

Positives

• The proposed reverse stock split is a proactive measure to address Nasdaq's minimum bid price requirement, potentially allowing the company to regain compliance and avoid full delisting.
• A higher stock price, if achieved, may increase investor interest, attract brokerage firm recommendations, and facilitate future financings.
• Maintaining a listing on a national exchange like Nasdaq is generally beneficial for a company's visibility, liquidity, and access to capital markets.
• The board's discretion to choose the exact ratio within the 1-for-5 to 1-for-20 range provides flexibility to respond to market conditions.

Negatives

• The necessity of a reverse stock split indicates a significantly low share price, reflecting underlying challenges or lack of investor confidence.
• The company's common stock was suspended from trading on Nasdaq and began trading on the OTCQX due to non-compliance with the $1.00 minimum bid price rule.
• There is no guarantee that the reverse stock split will result in a sustained increase in the per share price or that the company will meet all Nasdaq listing requirements.
• The liquidity of the common stock could be adversely affected by the reduced number of outstanding shares after the split.

Risks

• The reverse stock split may not result in an increase in the per share price of the common stock.
• The market price per share after the reverse stock split may not rise in proportion to the reduction in the number of shares outstanding.
• The reverse stock split may not result in a per share price that attracts brokers and investors who do not trade in lower-priced stocks.
• The reverse stock split may not result in a per share price that increases the company's ability to attract and retain employees.
• The market price per share may not exceed or remain in excess of the $1.00 minimum bid price required by Nasdaq for continued listing, or the company may not otherwise meet Nasdaq's requirements.
• If the reverse stock split is effected and the market price of the common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization may be greater than without the split.
• The liquidity of the common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.

Future Outlook

The company's board of directors, if the proposal is approved, will have the discretion to effect the reverse stock split at any time before September 5, 2026, with the goal of increasing the per share price to meet Nasdaq's minimum bid requirement and potentially facilitate future financings. The company intends to file a current report on Form 8-K with the final voting results within four business days after the Special Meeting.

Management Comments

• Our board of directors approved the proposal approving the Charter Amendment effecting the Reverse Stock Split and Reduction in Authorized Shares because it believes that: seeking stockholder approval and adoption of the Charter Amendment to effect the reverse stock split at the discretion of the board of directors is advisable and in the best interests of the Company and its stockholders.
• The Company's management believes that implementing a Reverse Stock Split may enable the shares of common stock to satisfy the minimum trading price requirement necessary to be listed on Nasdaq.
• Our board of directors believes that having our shares listed and trading on a national exchange would be beneficial to both the Company and its stockholders.
• Our management believes that most investment funds are reluctant to invest in lower priced stocks.
• If the Reverse Stock Split and Reduction in Authorized Shares successfully increases the per share price of our common stock, the board of directors believes this increase may increase trading volume in our common stock and facilitate future financings by the Company.

Industry Context

Biotechnology companies, particularly clinical-stage ones like Vaxart, often operate with significant cash burn and rely on capital markets for funding. Maintaining a listing on a major exchange like Nasdaq is crucial for liquidity, investor visibility, and access to institutional capital. Falling below minimum bid price requirements is a common challenge for smaller or struggling biotech firms, and a reverse stock split is a standard, albeit often last-resort, measure to regain compliance. While it addresses a listing issue, it does not fundamentally change the company's underlying business or clinical progress.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a reduction in the number of shares held, with a proportional increase in per-share price (if successful). Fractional shares will be cashed out. Percentage ownership will remain the same, but liquidity could be affected.
• Employees: A higher stock price, if sustained, may help the company attract and retain employees through equity compensation.
• Investors (General): A higher stock price may make the stock more appealing to brokerage firms and investment funds that are reluctant to trade in lower-priced securities.
• Nasdaq: The proposed action aims to bring the company back into compliance with Nasdaq listing rules, potentially allowing continued listing on the exchange.

Next Steps

• Stockholders to vote on the reverse stock split proposal at the Special Meeting on September 5, 2025.
• If approved, the board of directors will determine the exact reverse split ratio (between 1-for-5 and 1-for-20) and the effective date, which can be any time before September 5, 2026.
• The company will file a Certificate of Amendment to its Restated Certificate of Incorporation to effect the reverse stock split and proportional reduction in authorized shares.
• The company will continue its appeal of Nasdaq's delisting decision.
• Final voting results will be published in a current report on Form 8-K within four business days after the Special Meeting.

Key Dates

Recommendation

Vaxart is taking a necessary step to address its Nasdaq delisting issue by proposing a reverse stock split. While this action is crucial for maintaining exchange listing and potentially attracting broader investor interest, it is a reactive measure to a negative event (low stock price and delisting). The success of the reverse split in sustaining a higher price and regaining full Nasdaq compliance is not guaranteed, and the underlying business performance, which drives long-term value, is not addressed by this corporate action. Investors should hold to observe the outcome of the vote, the effect of the split, and any subsequent operational or clinical developments.

Keywords

Vaxart, VXRT, biotechnology, oral vaccines, reverse stock split, Nasdaq delisting, stock price, corporate governance, proxy statement, common stock, share reduction, OTCQX